Blogs

In this article, Dr. Fawzi Abou-Chahine, Grants Director at FI Group UK, delves into the evolving landscape of grant funding in the biotechnology sector.

TechBio's 2024 breakthroughs proved it’s not just innovating—it’s transforming healthcare, with the UK leading the charge into a future where biology, tech, and data redefine possibilities.

The BIA is driving progress across life sciences, from shaping policy in engineering biology and advocating for balanced perspectives in the Covid Inquiry to exhibiting UK innovation at J.P. Morgan Healthcare Week. 

In this blog, Maddie Cass, Senior Policy and Public Affairs Executive at the BIA, shares our perspective on the recent EngBio public trust survey findings conducted by the DSIT.

UK dealmakers are at the heart of JPM, the Government rolls out AI plan and new MHRA Chair sets priorities.

In this blog Izzy Webb, Deputy Director for technology, strategy and security in the Department for Science, Innovation and Technology (DSIT), discusses the UK Government's survey on engineering biology, outlining its limited public awareness but sharing optimism about its potential to address societal challenges.

Third-Party Cyber Security (TPCS) is a cyber security firm specialising in helping growth companies assure investors, partners, and customers that cyber security is well managed within the business.

In this guest blog, Christine Hockley, Managing Director at British Patient Capital, outlines the substantial long-term investment needed to scale innovations.

The global life science investment and media community are heading to the JPM Healthcare Conference next week and we’ll be keeping an eye on announcements and grants that impact our industry.

New legislation was laid in Parliament last Thursday to modernise the regulation of clinical trials in the UK.

It has been hugely exciting to partner with the BIA and its members as their charity of the year throughout 2024. We want to extend a heartfelt thank you to the BIA and all its member organisations for their incredible support, enthusiasm, and generosity.

As 2024 comes to a close, we’re proud to reflect on a year of championing the life sciences sector, from driving impactful policy changes to fostering connections across the UK and beyond. Dive into our key achievements, events, and milestones that shaped the year and set the stage for an exciting 2025.

As we engage as an Association in the development of the life science sector plan, the 10 year NHS plan and the UK’s industrial strategy this winter, this week I’ve been reflecting on what recent NHS announcements on adoption of innovation tell us.

Innovating manufacturing processes is key to revolutionising access to advanced cell and gene therapies - this blog explores how Tolemy Bio's co-founders, Caelan and Alex, are leveraging cutting-edge technologies like AI, biochemical modelling, and omics data to overcome complex challenges and drive global scalability.

When comparing the UK’s RNA manufacturing capability now, to that of before COVID-19, it is obvious that great advancements have been made. Abby Clark, Senior Manufacturing Programme Executive at the BIA, reflects on the past (nearly) five years and highlights recent work in the area.  

With a new Labour Government in place, this year’s event set the stage for impactful collaboration with MPs and policymakers. Read on to learn how we’re keeping life sciences at the top of the agenda.

The Innovation Ecosystem Programme, an 18-month-long NHS England project, which the BIA have been involved in throughout, describes how the UK can lead the way globally in health gains and life sciences powered growth. Its final report was published last week.

In this blog, John Stewart, Vice President of KojoX Strategy and Rasmus Pedersen, Associate Director of Process Technology for FUJIFILM Diosynth Biotechnologies, talk about FUJIFILM's flagship single-use cell culture facility in Billingham, UK.

In this guest blog, Luis Lacerda and Suzanne Farid from UCL explore the transformative potential of engineering biology and its critical role in addressing sustainability challenges in medicines manufacturing.

The North West of England is recognised as one of the cornerstones of the UK’s life sciences  sector. This enduring strength positions the North West as a hub of national significance for life sciences manufacturing.